Inflabloc Pharmaceuticals, Inc. is a privately-held pharmaceutical company located in Salt Lake City, Utah. The company is engaged in the research and development of pharmaceutical treatments for inflammatory disorders.

Inflabloc's research is based on the discovery and elucidation of anti-inflammatory properties of dehydroepiandrosterone (DHEA), a steroid that is produced in the adrenal gland. These properties are derived from DHEA's interruption of multiple pathways that can lead to pro-inflammatory cytokines.

© Copyright 2004. Inflabloc Pharmaceuticals, Inc.. All Rights Reserved.

Cytokine-based research is revolutionizing the treatment of inflammatory, infectious, and neoplastic diseases and currently has a $90 billion revenue potential.

Inflabloc Pharmaceuticals plans to leverage DHEA's anti-inflammatory properties into fixed combination drug products that incorporate DHEA as a primary active ingredient.

Inflabloc's product line contains three proprietary DHEA combinations that are currently being developed as treatments for gastrointestinal disorders as well as other inflammatory diseases.